Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?
- 1 January 1996
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 347 (8994), 102-103
- https://doi.org/10.1016/s0140-6736(96)90217-2
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible MechanismsNew England Journal of Medicine, 1995
- Lovastatin Inhibits Pancreatic Cancer Growth Regardless of RAS MutationPancreas, 1994
- Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatinThe Lancet, 1994
- Inhibition of Isoprenoid Biosynthesis Induces Apoptosis in Human Promyelocytic HL-60 CellsBiochemical and Biophysical Research Communications, 1994
- HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Lovastatin inhibits proliferation of rat mesangial cells.JCI Insight, 1993
- Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytesPharmacological Research, 1991
- Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and LovastatinThe Journal of Clinical Pharmacology, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.JCI Insight, 1985